The aim of our study was to retrospectively assess the efficacy and safety of systemic treatments in patients with alopecia areata, by recruiting cases from the HUGO network (Hôpitaux Universitaires du Grand Ouest), a network of 5 hospitals : Brest, Nantes, Rennes, Angers and Tours.

Inclusion Criteria:

• Patient with severe alopecia
• Has received at least one systemic treatment for at least 3 months (among methotrexate, intravenous or oral corticosteroid therapy, Ciclosporin, UVA/UVB phototherapy)
• Patient affiliated to a social security scheme
• Age greater than or equal to 18 years

Exclusion Criteria:

• Patients under legal protection (guardianship, curatorship, etc.)
• Refusal to participate
• Other cause of alopecia
• Follow-up less than 3 months
• Age under 18 years

Patients selected from 5 university hospitals in the HUGO network (Brest, Rennes, Tours, Angers, Nantes).

All collected data that underlie results in a publication

Data will be available beginning three years and ending fifteen years following the final study report completion

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement